Mutation drivers of immunological responses to cancer

Cancer Immunology Research

Volumn 4, Issue 9, 2016, Pages 789-798

  Porta Pardo, Eduard ^a   Godzik, Adam ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; BETA CATENIN; BIOLOGICAL MARKER; CADHERIN; COMPLEMENT; CTNNB1 PROTEIN, HUMAN; OSTEOBLAST CADHERIN; PROTEIN BINDING; TUMOR ANTIGEN;

ADRENAL CORTEX CARCINOMA; ARTICLE; CANCER TISSUE; CELL INFILTRATION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; MALIGNANT NEOPLASM; MELANOMA; PROTEIN DOMAIN; TUMOR IMMUNITY; ANTAGONISTS AND INHIBITORS; BIOLOGY; CHEMISTRY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MOLECULAR MODEL; MUTATION; NEOPLASM; PHENOTYPE; PROCEDURES; PROTEOMICS; STRUCTURE ACTIVITY RELATION;

ANTIGENS, NEOPLASM; BETA CATENIN; BIOMARKERS; CADHERINS; COMPLEMENT SYSTEM PROTEINS; COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOMODULATION; MODELS, MOLECULAR; MUTATION; NEOPLASMS; PHENOTYPE; PROTEIN BINDING; PROTEOMICS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85016134484     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0233     Document Type: Article

References (50)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
2. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Upregulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013;5:200ra116.
3. Duan F, Duitama J, Al Seesi S, Ayres CM, Corcelli SA, Pawashe AP, et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med 2014;211: 2231-48.
4. Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res 2014;2:522-9.
5. Hacohen N, Fritsch EF, Carter TA, Lander ES,Wu CJ. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res 2013;1:11-5.
6. Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 2014;124:453-62.
7. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N.Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015;160:48-61.
8. Kamburov A, Lawrence MS, Polak P, Leshchiner I, Lage K, Golub TR, et al. Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc Natl Acad Sci U S A 2015;112:E5486-95.
9. Mosca R, Tenorio-Laranga J, Olivella R, Alcalde V, Ceol A, Soler-Lopez M, et al. dSysMap: exploring the edgetic role of disease mutations. Nat Methods 2015;12:167-8.
10. Porta Pardo E, Godzik A.Analysis of individual protein regions provides novel insights on cancer pharmacogenomics. PLoS Comput Biol 2015;11: e1004024.
11. Wang X, Wei X, Thijssen B, Das J, Lipkin SM, Yu H.Three-dimensional reconstruction of protein networks provides insight into human genetic disease. Nat Biotechnol 2012;30:159-64.
12. Zhong Q, Simonis N, Li QR, Charloteaux B, Heuze F, Klitgord N, et al. Edgetic perturbation models of human inherited disorders. Mol Syst Biol 2009;5:321.
13. Porta-Pardo E, Garcia-Alonso L, Hrabe T, Dopazo J, Godzik A.A Pan-Cancer catalogue of cancer driver protein interaction interfaces. PLoS Comput Biol 2015;11:e1004518.
14. Porta-Pardo E, Godzik A.e-Driver: a novel method to identify protein regions driving cancer. Bioinformatics 2014;30:3109-14.
15. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013;4:2612.
16. Team RC. R: A language and environment for statistical computing 2015; R Foundation for Statistical Computing, Vienna, Austria.
17. Ginestet C.ggplot2: elegant graphics for data analysis. J R Stat Soc a Stat 2011;174:245-6.
18. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F.Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 2010;26:2069-70.
19. Yates A, Akanni W, Amode MR, Barrell D, Billis K, Carvalho-Silva D, et al. Ensembl 2016. Nucleic Acids Res 2016;44:D710-6.
20. Punta M, Coggill PC, Eberhardt RY, Mistry J, Tate J, Boursnell C, et al. The Pfam protein families database. Nucleic Acids Res 2012;40(Database issue):D290-301.
21. Prilusky J, Felder CE, Zeev-Ben-Mordehai T, Rydberg EH, Man O, Beckmann JS, et al. FoldIndex: a simple tool to predict whether a given protein sequence is intrinsically unfolded. Bioinformatics 2005;21:3435-8.
22. Xu D, Jaroszewski L, Li Z, Godzik A.AIDA: ab initio domain assembly for automated multi-domain protein structure prediction and domaindomain interaction prediction. Bioinformatics 2015;31:2098-105.
23. Cline MS, Craft B, Swatloski T, Goldman M, Ma S, Haussler D, et al. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Sci Rep 2013;3:2652.
24. Benjamini Y, Hochberg Y.Controlling the false discovery rate-A practical and powerful approach to multiple testing. J Roy Stat Soc B Met 1995;57: 289-300.
25. Shukla SA, Rooney MS, RajasagiM, Tiao G, Dixon PM, Lawrence MS, et al. Comprehensive analysis of cancer-Associated somatic mutations in class I HLA genes. Nat Biotechnol 2015;33:1152-8.
26. Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, Lund O, et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009;61:1-13.
27. Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W, et al. TCPA: a resource for cancer functional proteomics data. Nat Methods 2013;10:1046-7.
28. Gaujoux R, Seoighe C.CellMix: a comprehensive toolbox for gene expression deconvolution. Bioinformatics 2013;29:2211-2.
29. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015;12:453-7.
30. Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013;45:1113-20.
31. Spranger S, Bao R,Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015;523:231-5.
32. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74.
33. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015;350:207-11.
34. Betts MJ, Lu Q, Jiang Y, Drusko A, Wichmann O, Utz M, et al. Mechismo: predicting the mechanistic impact of mutations and modifications on molecular interactions. Nucleic Acids Res 2015;43:e10.
35. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. Cancer and the complement cascade. Mol Cancer Res 2010;8:1453-65.
36. Janelle V, Langlois MP, Tarrab E, Lapierre P, Poliquin L, Lamarre A.Transient complement inhibition promotes a tumor-specific immune response through the implication of natural killer cells. Cancer Immunol Res 2014;2:200-6.
37. Pio R, Corrales L, Lambris JD. The role of complement in tumor growth. Adv Exp Med Biol 2014;772:229-62.
38. Barthel D, Schindler S, Zipfel PF. Plasminogen is a complement inhibitor. J Biol Chem 2012;287:18831-42.
39. Borkowska S, Suszynska M, Mierzejewska K, Ismail A, Budkowska M, Salata D, et al.Novel evidence that crosstalk between the complement, coagulation and fibrinolysis proteolytic cascades is involved inmobilization of hematopoietic stem/progenitor cells (HSPCs). Leukemia 2014;28:2148-54.
40. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008;9:1225-35.
41. Campa MJ, Gottlin EB, Bushey RT, Patz EF Jr. Complement factor H antibodies from lung cancer patients induce complement-dependent lysis of tumor cells, suggesting a novel immunotherapeutic strategy. Cancer Immunol Res 2015;3:1325-32.
42. Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol 2012;189:4674-83.
43. Gunn L, Ding C, Liu M, Ma Y, Qi C, Cai Y, et al. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J Immunol 2012;189:2985-94.
44. Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol 2015;33:445-74.
45. Chiu YH, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 2009;138:576-91.
46. Ishikawa H, Barber GN. The STING pathway and regulation of innate immune signaling in response to DNA pathogens. Cell Mol Life Sci 2011; 68:1157-65.
47. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferondependent antitumor immunity in immunogenic tumors. Immunity 2014;41:843-52.
48. Wang L, Zhou Y, Xu L, Xiao R, Lu X, Chen L, et al. Molecular basis for 5-carboxycytosine recognition by RNA polymerase II elongation complex. Nature 2015;523:621-5.
49. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013;39:782-95.
50. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015;21:938-45.